Oppenheimer analyst Michael Wiederhorn is updating its Amedisys (AMED) model following the Q4 earnings release. Amedisys is currently in the process of being acquired by UnitedHealth (UNH). In response to the DOJ’s November 2024 lawsuit to block the transaction, UnitedHealth disclosed in February 2025 a plan to divest at least 128 locations. A court trial has been scheduled for 10/27/2025, but that may be rescheduled to 2/9/2026, the firm says. Due to potential uncertainty associated with the merger’s closing, Oppenheimer is adjusting its rating to Perform from Not Rated.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMED:
- Amedisys Reports 2024 Financial Results Amid Merger Plans
- Amedisys Hold Rating: Mixed Performance and Cost Pressures Amid Regulatory Uncertainties
- Amedisys Reports Q4 2024 Financial Results Amid Merger Plans
- Amedisys reports Q4 adjusted EPS 96c, consensus $1.06
- Amedisys Inc (AMED) Q4 Earnings Cheat Sheet